Tonix Pharmaceuticals Holding (TNXP) Net Equity Issued and Repurchased (2010 - 2026)

Tonix Pharmaceuticals Holding's Net Equity Issued and Repurchased history runs 15 years deep, the most recent figure standing at $20.1 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased fell 67.66% year-over-year to $20.1 million in Q1 2026; TTM through Mar 2026 was $195.8 million, a 2.52% decrease from a year earlier, with the FY2025 full-year figure at $237.9 million, up 69.72% from the prior year.
• Net Equity Issued and Repurchased slipped to $20.1 million in Q1 2026 per TNXP's latest filing, from $67.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $94.9 million in Q3 2025 and bottomed at -$30.7 million in Q3 2022.
• The 5-year median for Net Equity Issued and Repurchased is $13.6 million (2022), against an average of $28.7 million.
• Across the five-year window, Net Equity Issued and Repurchased slumped 181.04% in 2022 and surged 833.25% in 2024, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $13.3 million in 2022, then plunged by 31.07% to $9.2 million in 2023, then jumped by 833.25% to $85.9 million in 2024, then fell by 22.02% to $67.0 million in 2025, then plunged by 69.94% to $20.1 million in 2026.
• Per Business Quant, the three latest TNXP Net Equity Issued and Repurchased figures stand at $20.1 million (Q1 2026), $67.0 million (Q4 2025), and $94.9 million (Q3 2025).